Personalized RA treatment: genes may predict drug success

NCT ID NCT07388407

Recruiting now Knowledge-focused Sponsor: Foundation University Islamabad Source: ClinicalTrials.gov ↗

First seen Feb 05, 2026 · Last updated May 21, 2026 · Updated 22 times

Summary

This study looks at how a person's genes influence their response to leflunomide, a common rheumatoid arthritis (RA) medication. Researchers will recruit 110 Pakistani adults with RA who are taking leflunomide alone. They will collect blood samples to analyze DNA and track treatment effectiveness and side effects over 6 months. The goal is to create a genetic guide to help doctors choose the best treatment for each patient.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEMATOID ARTHRITIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fauji Foundation Hospital, Rawalpindi
RECRUITING

Rawalpindi, Punjab Province, 46000, Pakistan

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Shifa International Hospital
COMPLETED

Islamabad, Punjab Province, 44000, Pakistan

Conditions

Explore the condition pages connected to this study.

RHEMATOID ARTHRITIS